Aurinia Pharmaceuticals Inc. (AUPH)
|52 Week Range||4.07-13.415|
|1y Target Est||-|
|DCF Unlevered||AUPH DCF ->|
|DCF Levered||AUPH LDCF ->|
|Debt / Equity||16.14%||Neutral|
Upgrades & Downgrades
Latest AUPH news
Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet
24 March 2023
LUPKYNIS has had a lengthy and ultimately productive development pathway. Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch.
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript
28 February 2023
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Pet...
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
28 February 2023
Aurinia (AUPH) delivered earnings and revenue surprises of 30.77% and 0.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
23 February 2023
We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
These 2 Healthcare Stocks Have Doubled in 2023
2 February 2023
Many traders are attracted to low-priced stocks because they come with the allure of 2x, 3x or greater short-term gains. For fundamentalists, the challenge is finding such companies that have establis...
Why Shares of Aurinia Pharmaceuticals Soared This Week
6 January 2023
A patent settlement and improved financials sent the stock soaring.
Aurinia's Patent Dispute Is Over, But Without A Buyout, There's No Upside
5 January 2023
Aurinia Pharmaceuticals Inc. recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter.
Aurinia Pharmaceuticals: Lupkynis Patent Settlement Removes Overhang
5 January 2023
Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and countercla...
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
4 January 2023
VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is sche...
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >